{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:39:17Z","timestamp":1792607957956,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.atherosclerosis.2012.02.016","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T06:40:29Z","timestamp":1329374429000},"page":"251-261","source":"Crossref","is-referenced-by-count":241,"title":["Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials"],"prefix":"10.1016","volume":"223","author":[{"given":"Doralisa","family":"Morrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0015","series-title":"Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","article-title":"2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0030","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0035","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ahj.2008.05.020","article-title":"Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease","volume":"156","author":"Steinberg","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1074248408328927","article-title":"Management of hyperlipidemia in older adults","volume":"14","author":"Alexander","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/HCR.0b013e318192754e","article-title":"A\u00a0review of lipid management in primary and secondary prevention","volume":"29","author":"Dembowski","year":"2009","journal-title":"J\u00a0Cardiopulm Rehabil Prev"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0065","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1194\/jlr.P900004-JLR200","article-title":"Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and\/or simvastatin in men","volume":"50","author":"Sudhop","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","article-title":"Niemann-Pick C1-Like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport","volume":"73","author":"Jia","year":"2011","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbalip.2011.05.013","article-title":"Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver","volume":"1811","author":"Tang","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0080","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/clp.10.49","article-title":"Update on the efficacy and safety of combination ezetimibe plus statin therapy","volume":"5","author":"Toth","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0085","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0090","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0002-9149(02)03236-8","article-title":"Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia","volume":"91","author":"Kerzner","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0095","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"24","author":"Melani","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0100","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4065\/79.5.620","article-title":"Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial","volume":"79","author":"Goldberg","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0110","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2004.02.059","article-title":"Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals","volume":"93","author":"Feldman","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0115","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0120","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0125","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (vytorin) versus atorvastatin in patients with hypercholesterolemia: the vytorin versus atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0130","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0135","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0140","first-page":"772","article-title":"Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia","volume":"98","author":"Rodney","year":"2006","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0145","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.amjcard.2009.05.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)","volume":"103","author":"Robinson","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0150","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0155","doi-asserted-by":"crossref","first-page":"227A","DOI":"10.1016\/S0735-1097(03)81639-X","article-title":"Coadministration of ezetimibe with simvastatin","volume":"41","author":"Dobs","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0165","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1463-1326.2004.00420.x","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients","volume":"7","author":"Gaudiani","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A\u00a0community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0175","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1185\/030079905X382004","article-title":"LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia","volume":"21","author":"Brohet","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijcard.2005.01.022","article-title":"Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease","volume":"102","author":"Farnier","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0185","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1368-5031.2005.00565.x","article-title":"Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease","volume":"59","author":"Cruz-Fernandez","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0190","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1368-5031.2005.00714.x","article-title":"Lipid-altering efficacy of switching from atorvastatin 10mg\/day to ezetimibe\/simvastatin 10\/20mg\/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease","volume":"59","author":"Barrios","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0195","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1463-1326.2007.00725.x","article-title":"Efficacy of ezetimibe\/simvastatin 10\/20 and 10\/40mg compared with atorvastatin 20mg in patients with type 2 diabetes mellitus","volume":"9","author":"Constance","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0200","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2008.09.075","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (20mg) versus uptitration of atorvastatin (to 40mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease","volume":"102","author":"Conard","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0205","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.amjcard.2008.09.076","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (40mg) compared with uptitration of atorvastatin (to 80mg) in hypercholesterolemic patients at high risk of coronary heart disease","volume":"102","author":"Leiter","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0210","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1742-1241.2009.02022.x","article-title":"Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy \u2013 The IN-CROSS study","volume":"63","author":"Farnier","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0215","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjcard.2009.10.029","article-title":"Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40mg in Patients > or=65 years of age (from the ZETia in the ELDerly [ZETELD] study)","volume":"105","author":"Zieve","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/1745509X.3.6.691","article-title":"Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65\u201374 and 75 years and older","volume":"3","author":"Robinson","year":"2007","journal-title":"Aging Health"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1476-511X-10-146","article-title":"Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients","volume":"10","author":"Abramson","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0230","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1463-1326.2011.01383.x","article-title":"Lipid-altering efficacy and safety profile of combination therapy with ezetimibe\/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials","volume":"13","author":"Leiter","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0235","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0240","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0245","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0250","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1185\/03007995.2011.571239","article-title":"Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis","volume":"6","author":"Mikhailidis","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0255","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/13543784.11.11.1587","volume":"11","author":"Bays","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0260","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/01.ATV.20.5.1340","article-title":"Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol","volume":"20","author":"Miettinen","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0265","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1194\/jlr.P800042-JLR200","article-title":"Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers","volume":"50","author":"van Himbergen","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0270","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2011.06.010","article-title":"Where does the interplay between cholesterol absorption and synthesis in the context of statin and\/or ezetimibe treatment stand today?","volume":"217","author":"Descamps","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0275","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1073\/pnas.0508483103","article-title":"Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels","volume":"103","author":"Cohen","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0280","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ygeno.2005.08.007","article-title":"Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment","volume":"86","author":"Simon","year":"2005","journal-title":"Genomics"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0285","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacl.2007.12.006","article-title":"Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice","volume":"2","author":"Sniderman","year":"2008","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0290","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A\u00a0meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcome"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2011.10.043","article-title":"Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus","volume":"220","author":"Winkler","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0300","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacc.2008.04.052","volume":"52","author":"Ballantyne","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0305","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosissup.2005.02.005","article-title":"Markers of inflammation and their clinical significance","volume":"6","author":"Ballantyne","year":"2005","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0315","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","article-title":"Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)","volume":"106","author":"Ridker","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0320","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacl.2011.07.005","article-title":"Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists","volume":"5","author":"Davidson","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2012.02.016_bib0325","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2010.03.004","article-title":"An update on the IMProved reduction of outcomes: vytorin efficacy international trial (IMPROVE-IT) design","volume":"159","author":"Califf","year":"2010","journal-title":"Am Heart J"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501200130X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501200130X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T23:25:41Z","timestamp":1543188341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501200130X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S002191501200130X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.02.016","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}